Participants in the study will be adults who have a history of a heart rhythm disorder known as atrial fibrillation and have suffered from a spontaneous intracerebral hemorrhage. The study will assess various outcomes over a period of 24 months, including the occurrence of major vascular events, overall survival, and quality of life. The study aims to determine the best approach to prevent future vascular events in these patients.

Throughout the study, participants will be monitored for any major health events, such as cardiovascular or cerebrovascular incidents, and their overall health and quality of life will be evaluated. The study will also look at specific markers of small-vessel diseases in the brain using imaging techniques like MRI. The goal is to find a balance between preventing further bleeding and reducing the risk of blood clots in patients who have experienced a brain hemorrhage.

Participants in this trial will be assigned to receive either levetiracetam, which may be given as film-coated tablets for oral use or as a solution for infusion through a vein, or a placebo. This is a randomised study, meaning participants are placed into groups by chance, and it is double-blind, so neither the participants nor the researchers know which treatment is being administered during the process. The study will involve monitoring participants over several months to observe how the treatment affects their overall health and independence.

Participants in the trial will be assigned to receive either diroximel fumarate or a placebo. The study is designed so that neither the participants nor the researchers know which treatment is being administered. During the course of the study, the amount of swelling will be monitored using a computed tomography scan, which is a medical imaging test that uses X-rays to create detailed pictures of the brain. The progress of the participants will be followed for six months to observe long-term effects and safety.

The purpose of this research is to examine how the brain’s immune response around the area of bleeding influences a patient’s recovery after six months. The study involves receiving a single injection of 18F-DPA-714 approximately 10 days after the brain bleeding occurs. This substance helps create detailed images of inflammation in the brain using a special type of scan called PET (Positron Emission Tomography).

During the study, participants will undergo brain imaging tests, including MRI scans, to examine how the protective barrier of the brain (called the blood-brain barrier) is affected by the bleeding. Blood samples will also be collected to measure various substances that indicate inflammation in the body. Patients will be monitored for six months to track their recovery progress.

The purpose of this research is to determine whether starting oral antiplatelet medication alone is more beneficial than avoiding these medications in preventing future cardiovascular and brain-related health events in people who have survived a brain hemorrhage. The study compares two groups of patients – one group receiving antiplatelet medication and another group receiving standard care without antiplatelet medication.

The treatment period lasts for 60 months, during which patients will take their assigned medication daily. Throughout the study, doctors will monitor patients for various health events, particularly focusing on strokes, heart attacks, and other cardiovascular conditions. The medications are taken as tablets by mouth once daily.

Participants in the study will receive either Esketamine Hydrochloride or Sodium Chloride through an infusion, which is a method of delivering medication directly into the bloodstream. The treatment will last for a maximum of 14 days. During this time, researchers will monitor the patients to see how often these brain activities occur and to check for any side effects or reactions to the treatment. The study aims to understand if Esketamine Hydrochloride can help patients whose brain activities continue despite other treatments.

After the treatment period, the study will continue to follow up with participants to assess their recovery and overall health outcomes. This will include evaluating their functional abilities six months after the treatment using standard scales like the modified Rankin Scale and the Glasgow Outcome Scale-Extended. The results of this study could provide valuable insights into new treatment options for individuals with severe brain injuries.

Participants in the study will be monitored over a period of 24 months. During this time, researchers will compare the outcomes of those who continue taking statins with those who stop. The study will also assess the quality of life and cognitive functions, which relate to thinking and memory, using tools like the EQ-5D questionnaire and the Telephone Montreal Cognitive Assessment (T-MoCA). The study will also explore the role of certain genetic factors, specifically the APOE gene, in the risk of having another ICH.

The goal of this research is to provide better guidance on the use of statins in patients who have had an ICH, helping to balance the benefits of cholesterol management with the potential risks of recurrent bleeding in the brain. This information could be crucial for doctors and patients in making informed decisions about the continuation or discontinuation of statin therapy after an ICH.

The purpose of the study is to evaluate how effective naloxegol is in preventing early constipation and lung infections in patients with brain injuries who are being treated with opioids. Participants in the study will receive either the medication or a placebo, which looks like the medication but does not contain the active ingredient. The study will follow patients to see if they experience any bowel movements or lung infections during their hospital stay.

Throughout the study, researchers will monitor various aspects of the patients’ health, such as their ability to meet nutritional goals, the need for additional medications to manage vomiting or constipation, and the length of time they require mechanical ventilation. The study will also track the overall recovery of patients over a period of six months, using a scale called the Glasgow Outcome Scale Extended (GOSE), which measures recovery after brain injury. The study is expected to continue until September 2026.

Participants in the study will receive either the new treatment or a placebo. The study will monitor various health indicators to ensure the safety of the participants, such as checking for any adverse events, conducting physical and neurological examinations, and performing blood tests to assess biochemistry and coagulation. The study will also use CT scans to measure changes in the volume of the hemorrhage and other related factors.

The study is designed to provide important information about the potential benefits and risks of using Ir-CPI in treating spontaneous intracerebral hemorrhage. By participating in this study, researchers hope to gather data that could lead to new treatment options for this serious condition. The study is expected to continue for several years to ensure comprehensive results are obtained.

Participants in the study will receive either a high dose or a low dose of anakinra, or they will continue with standard medical care. The medication is administered as an injection. The study will monitor the effects of the treatment over a period of time, looking specifically at how it impacts brain swelling, which will be assessed using MRI scans. Additionally, the study will track any side effects and changes in certain blood markers that indicate inflammation.

The trial aims to provide valuable insights into whether anakinra can help reduce the harmful effects of brain swelling following an intracerebral hemorrhage. This could potentially lead to improved treatment options for patients who suffer from this serious condition. The study is expected to continue until 2025, with recruitment starting in late 2024.